Fulcrum Therapeutics/$FULC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Fulcrum Therapeutics
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Ticker
$FULC
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
45
Website
FULC Metrics
BasicAdvanced
$364M
-
-$1.18
2.38
-
Price and volume
Market cap
$364M
Beta
2.38
52-week high
$10.13
52-week low
$2.32
Average daily volume
864K
Financial strength
Current ratio
24.415
Quick ratio
23.978
Long term debt to equity
2.462
Total debt to equity
3.532
Profitability
EBITDA (TTM)
-81.275
Management effectiveness
Return on assets (TTM)
-19.76%
Return on equity (TTM)
-30.00%
Valuation
Price to book
1.7
Price to tangible book (TTM)
1.7
Price to free cash flow (TTM)
-6.417
Free cash flow yield (TTM)
-15.58%
Free cash flow per share (TTM)
-1.049
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
261.44%
3-year earnings per share growth (CAGR)
-23.39%
What the Analysts think about FULC
Analyst ratings (Buy, Hold, Sell) for Fulcrum Therapeutics stock.
Bulls say / Bears say
Analysts at Leerink Partners upgraded Fulcrum Therapeutics from 'market perform' to 'outperform' with a price target increase from $4.00 to $12.00, indicating strong confidence in the company's future prospects. (defenseworld.net)
Cantor Fitzgerald raised its rating on Fulcrum Therapeutics from 'neutral' to 'overweight' and set a $10.00 price target, reflecting a positive outlook on the company's performance. (nasdaq.com)
Fulcrum Therapeutics completed enrollment in the 12 mg dose cohort of the Phase 1b PIONEER trial for pociredir in sickle cell disease and initiated the 20 mg dose cohort, demonstrating progress in their clinical pipeline. (globenewswire.com)
Despite recent upgrades, the consensus rating for Fulcrum Therapeutics remains 'Hold,' with an average price target of $5.83, suggesting limited upside potential. (defenseworld.net)
HC Wainwright maintained a 'neutral' rating with a $4.00 price target, indicating cautious sentiment regarding the company's near-term performance. (defenseworld.net)
The company's stock has experienced significant volatility, with a 52-week range between $2.32 and $10.13, which may concern risk-averse investors. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
FULC Financial Performance
Revenues and expenses
FULC Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fulcrum Therapeutics stock?
Fulcrum Therapeutics (FULC) has a market cap of $364M as of August 01, 2025.
What is the P/E ratio for Fulcrum Therapeutics stock?
The price to earnings (P/E) ratio for Fulcrum Therapeutics (FULC) stock is 0 as of August 01, 2025.
Does Fulcrum Therapeutics stock pay dividends?
No, Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Fulcrum Therapeutics dividend payment date?
Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders.
What is the beta indicator for Fulcrum Therapeutics?
Fulcrum Therapeutics (FULC) has a beta rating of 2.38. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.